November 2024, Vol 14, No 11

Osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) has received another new indication,... Read More ›

Officials with the FDA have approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone for adults... Read More ›

Amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed has been green-lighted by the FDA for adult patients... Read More ›

On September 17, 2024, FDA officials approved pembrolizumab (Keytruda, Merck)... Read More ›

This publication provides ongoing lists of US-based trials that are actively recruiting. This issue is focused on pancreatic cancer because November is Pancreatic Cancer Awareness Month. Read More ›